Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/2012
Full metadata record
DC FieldValueLanguage
dc.contributorTabb, Jocelynen_US
dc.contributorDimond, Reneeen_US
dc.contributorBowen, Danielaen_US
dc.contributorDening, Kaitlinen_US
dc.date.accessioned2022-12-16T01:54:20Z-
dc.date.available2022-12-16T01:54:20Z-
dc.date.issued2022-
dc.identifier.govdoc01972en_US
dc.identifier.urihttp://hdl.handle.net/11054/2012-
dc.description.abstractBackground: COVID-19 provided unprecedented global challenges to the delivery of health services, including the need for rapid implementation of innovative workflows to determine eligibility and safety of oral COVID-19 therapies. The model developed for ‘at home’ patients will be described. Objective: To provide a fully integrated, patient-centred, 7 day per week, multidisciplinary team approach to provision of oral COVID-19 therapies for patients isolating at home via National Medicines Stockpile (N) or Pharmaceutical Benefits Schedule (PBS) criteria. Action: Medical staff working remotely stratified patient eligibility for either Paxlovid (nirmatrelvir/ritonavir) or Lagevrio (molnupiravir) then referred onto the pharmacy service via Tea or email for comprehensive medication assessment. The pharmacy service included: telehealth consultation with the patient encompassing medication history interview; interaction checks; recommendations to the prescriber; patient counselling on the medication, interactions, recommended medication changes; documentation in patient’s electronic medical record, and follow-up from a pharmacist at the end of the treatment. Medication supply logistics were coordinated by the pharmacy technician. Evaluation: Over 2 months, 67 patients were referred to the pharmacy service, with 71% of pharmacist consultations occurring via telehealth. 63% of patients had a high complexity rating based on number of medicines and potential for interactions, and 93% of pharmacist recommendations were implemented. 82% of patients rated the service as excellent. The pharmacy service is an essential and valued step in the multidisciplinary model of care designed to provide optimal COVID-19 treatment at home. Discussion: The requirement to review medication histories and interactions before prescribing COVID-19 therapies, all remotely, forced the development of innovative models of interdisciplinary teamwork and patient interaction. The use of telehealth was integral in allowing provision of a model of care that was responsive, patient focused and effective. This model has the potential to be utilised in other areas of pharmacy practice.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2022-12-13T00:18:26Z No. of bitstreams: 1 C05 Jocelyn Tabb Surfing the Pandemic Wave Innovate or Drown. A Novel Pharmacy Model for COVID-19 Oral Therapy.pptx: 9317266 bytes, checksum: f1c7b14263a585f744f28d4ee96729f2 (MD5)en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2022-12-16T01:54:20Z (GMT) No. of bitstreams: 1 C05 Jocelyn Tabb Surfing the Pandemic Wave Innovate or Drown. A Novel Pharmacy Model for COVID-19 Oral Therapy.pptx: 9317266 bytes, checksum: f1c7b14263a585f744f28d4ee96729f2 (MD5)en
dc.description.provenanceMade available in DSpace on 2022-12-16T01:54:20Z (GMT). No. of bitstreams: 1 C05 Jocelyn Tabb Surfing the Pandemic Wave Innovate or Drown. A Novel Pharmacy Model for COVID-19 Oral Therapy.pptx: 9317266 bytes, checksum: f1c7b14263a585f744f28d4ee96729f2 (MD5) Previous issue date: 2022en
dc.titleSurfing the pandemic wave: innovate or drown? A novel pharmacy model for COVID-19 oral therapy.en_US
dc.typeConferenceen_US
dc.type.specifiedPresentationen_US
dc.bibliographicCitation.conferencedateDecember 1-3en_US
dc.bibliographicCitation.conferencenameMedicines Management 2022: The 46th SHPA National Conferenceen_US
dc.bibliographicCitation.conferenceplaceBrisbaneen_US
dc.subject.healththesaurusCOVID-19en_US
dc.subject.healththesaurusCORONAVIRUSen_US
dc.subject.healththesaurusSERVICE REDESIGNen_US
dc.subject.healththesaurusPHARMACYen_US
Appears in Collections:Research Output



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.